Long Term Hepatitis A Virus (HAV) Antibody Persistence in Children Vaccinated With 1 Dose and Those Vaccinated With 2 Doses of Havrix in Panama

Trial Profile

Long Term Hepatitis A Virus (HAV) Antibody Persistence in Children Vaccinated With 1 Dose and Those Vaccinated With 2 Doses of Havrix in Panama

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Hepatitis A vaccine inactivated (Primary)
  • Indications Hepatitis A
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jul 2017 Planned End Date changed from 1 Nov 2018 to 20 Mar 2020.
    • 10 Jul 2017 Planned primary completion date changed from 1 Nov 2018 to 20 Mar 2020.
    • 04 Oct 2016 Planned End Date changed from 1 Aug 2017 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top